XM tidak memberikan layanan kepada penduduk Amerika Serikat.

Web browsing tracking doesn't violate Massachusetts wiretap law, court rules



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Web browsing tracking doesn't violate Massachusetts wiretap law, court rules</title></head><body>

By Nate Raymond

Oct 24 (Reuters) -Massachusetts' top court on Thursday held that a 1960s law prohibiting eavesdropping on phone calls does not bar website operators from collecting users' browsing activities without their consent using analytics tools including ones produced by Meta PlatformsMETA.O and Alphabet's GOOGL.O Google.

The Massachusetts Supreme Judicial Court on a 5-1 vote ruled in favor of two hospitals seeking to dismiss proposed class action lawsuits alleging they violated the privacy of users of their websites by holding that the state's wiretap statute did not cover the tracking of a person's web browsing.

The lawsuits were being closely watched by business groups, which had warned of the risk of exposing thousands of commercial website operators to liability for using popular website analytics tools like Google Analytics and Meta Pixel.

Justice Scott Kafker, writing for the majority, said that when Massachusetts Wiretap Act was enacted, "wiretaps involved the interception of person-to-person conversations and messages using hidden electronic surveillance devices placed in people's homes or businesses or tapping their telephone lines."

He said the law was expansive enough to prohibit eavesdropping on more modern means of communication, including text messages, internet chats and e-mails messages than what the legislature could have imagined in 1968.

But Kafker said the browsing tracking activities that occur when someone uses the websites of Beth Israel Deaconess Medical Center and New England Baptist Hospital do not involve person-to-person conversations the law clearly intended to protect.

"If the Legislature intends for the wiretap act's criminal and civil penalties to prohibit the tracking of a person's browsing of, and interaction with, published information on websites, it must say so expressly," Kafker wrote.

The lawsuits were filed in 2023 by the same lead plaintiff, Kathleen Vita, who said she regularly visited both hospitals' websites and that they illegally transmitted users' browsing activities to Google and Meta without her permission.

The hospitals said those lawsuits would have exposed them to "massive" damages if allowed to proceed based on the financial penalties in the law. A website with just 1,000 unique visitors per day would face at least $36 million in damages per year over a three-year statute-of-limitations period under Vita's legal theory, they said.

Lawyers for the hospitals and Vita did not respond to requests for comment.

Hundreds of similar cases have been filed nationally, and the U.S. Chamber of Commerce in an amicus brief had expressed concern that the Massachusetts' court could buck a trend in which courts in other states had tossed such cases.

In Massachusetts, the first such case, against the healthcare system now called Mass General Brigham, settled for $18.4 million in 2022. At least 24 other cases have been filed in Massachusetts since then, including the two decided Thursday.

In a dissenting opinion, Justice Dalila Argaez Wendlandt said the hospitals at issue understood their websites were a means to communicate privately with patients yet aided third parties to record their healthcare information.

"The court decides that the wiretap act provides no recourse despite its prohibition on surreptitious electronic surveillance by private parties," she wrote. "Lamentably, the court is right about one thing; the Legislature will need to correct today's error."

The case is Kathleen Vita v. New England Baptist Hospital, et al, Massachusetts Supreme Judicial Court, No. SJC-13542.

For the plaintiffs: Patrick Vallely of Shapiro Haber & Urmy

For the hospitals: David Gacioch of McDermott Will & Emery


Read more:

Massachusetts top court considers allowing website tracking class actions

Biden-era policy against hospital web trackers unlawful, judge rules



Reporting by Nate Raymond in Boston

</body></html>

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.